Plain-English translation of NCT07327021 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether patients with triple-negative breast cancer (an aggressive form of the disease) can reduce their chemotherapy burden safely. You would receive four months of chemotherapy combined with pembrolizumab, an immune-boosting medication. If your tumor disappears completely on an MRI scan, you might be able to skip the second four months of additional chemotherapy that is normally given—avoiding serious side effects while maintaining good survival outcomes.
The standard treatment for this cancer type uses five different drugs over eight months, which can cause serious heart problems and increase the risk of future blood cancers. Many patients show excellent response after just the first four months, raising the question of whether additional chemotherapy is truly necessary for everyone.
You likely qualify if…
You likely don't qualify if…
You would receive four months (16 weeks) of intravenous chemotherapy combined with pembrolizumab, given in cycles. During this time, you would have regular visits for treatment and blood tests. After four months, you would have an MRI scan to see how well your tumor has responded. Depending on the scan results, your doctor will decide whether you continue with the second four months of chemotherapy or can stop here. Throughout the study, you would be closely monitored for side effects and your health would be tracked for at least a year after treatment ends.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Israel